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a b s t r a c t
Redox networks in the cell integrate signaling pathways that control metabolism, energetics, cell
survival, and death. The physiological second messengers that modulate these pathways include nitric
oxide, hydrogen peroxide, and electrophiles. Electrophiles are produced in the cell via both enzymatic
and nonenzymatic lipid peroxidation and are also relatively abundant constituents of the diet. These
compounds bind covalently to families of cysteine-containing, redox-sensing proteins that constitute the
electrophile-responsive proteome, the subproteomes of which are found in localized intracellular
domains. These include those proteins controlling responses to oxidative stress in the cytosol—notably
the Keap1-Nrf2 pathway, the autophagy-lysosomal pathway, and proteins in other compartments
including mitochondria and endoplasmic reticulum. The signaling pathways through which electro-
philes function have unique characteristics that could be exploited for novel therapeutic interventions;
however, development of such therapeutic strategies has been challenging due to a lack of basic
understanding of the mechanisms controlling this form of redox signaling. In this review, we discuss
current knowledge of the basic mechanisms of thiol-electrophile signaling and its potential impact on
the translation of this important ﬁeld of redox biology to the clinic. Emerging understanding of thiol-
electrophile interactions and redox signaling suggests replacement of the oxidative stress hypothesis
with a new redox biology paradigm, which provides an exciting and inﬂuential framework for guiding
translational research.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Introduction
In the ﬁeld of free radical biology, the “oxidative stress paradigm”
has been the central dogma that has provided the framework for
understanding the mechanisms leading to the development of novel
therapeutics. It is an attractive concept that simply postulates that
there is a balance between free radicals or oxidants [commonly called
reactive oxygen species (ROS) or reactive species] with antioxidants in
normal physiology. Pathology occurs when reactive species are
produced in excess of the endogenous antioxidants, and this leads to
indiscriminate damage to cellular macromolecules (proteins, lipids,
and DNA) and kills cells [1]. Interestingly, much of the evidence for this
process occurring in health and disease is derived from the oxidative
modiﬁcations of proteins by products of lipid peroxidation—the
reactive lipid species [2–6]. Accordingly, the development of thera-
peutics initially focused on developing compounds that could termi-
nate the lipid peroxidation chain reaction such as α-tocopherol or
dietary-derived polyphenolics [7].
The oxidative stress paradigm resulted in the widespread notion
that supplementation of dietary antioxidants that target lipid perox-
idation will prevent many human diseases. Over time, the mechan-
istic basis of the concept was largely forgotten and instead of the
oxidative stress hypothesis becoming more precise in terms of
molecular targets and mechanism, it became diffuse and nonspeciﬁc.
This has unfortunately resulted in the widely held belief that all ROS
are extremely reactive and share common biophysical properties and
that all antioxidants are then also capable of scavenging any reactive
species irrespective of the biochemical mechanism. The antioxidants
which have achieved most attention in this respect are those that
intercept lipid radicals and include α-tocopherol (vitamin E), β-
carotene, ascorbic acid (vitamin C), and the numerous natural
polyphenolic compounds present in the diet [8–10]. However,
despite excellent animal model studies, basic research, and epide-
miological data that collectively show that oxidative protein mod-
iﬁcations by reactive lipid species are increased in many chronic
diseases, controlled clinical trials with lipid radical scavenging
antioxidants have not yielded the anticipated beneﬁts [6,11–19].
It is now clear that several critical predictions of the oxidative
stress paradigm are not supported by experiment. Using advanced
mass spectrometry techniques, it has become possible to measure
both the frequency of modiﬁcation of biomolecules by reactive
species and their levels in vivo. In direct contrast to the predictions
from the oxidative stress paradigm in oxidant-dependent patholo-
gies, the relative levels of protein modiﬁcation are extremely low,
and antioxidants are still abundantly present in the cells and tissues
[20,21]. In addition, the hypothesis predicts that exogenous oxidants
should contribute to pathology. This is indeed the case, but the levels
of exogenous oxidants needed to place the system out of balance
in vitro and in vivo are orders of magnitude higher than the levels
that can ever be produced in biology in either health or disease.
At the inception of the oxidative stress hypothesis, the concept
that endogenous molecules such as nitric oxide or hydrogen
peroxide played a role in cell signaling had not been developed.
It is now clear that not only do low levels (typically 10–100 nM) of
these compounds play a role in cell signaling, but, as with other
signaling pathways, control is exerted in speciﬁc domains which
are not in redox equilibrium with the rest of the cell. We have
proposed that endogenous antioxidants serve as redox insulators
of these cell signaling domains [22]. Because exogenous signaling
molecules such as hydrogen peroxide must break down the redox
insulation before an effect can be observed, high nonphysiological
concentrations are often needed. Thus, the idea that “free radicals
are bad and antioxidants are good” is clearly undergoing a critical
and high-proﬁle reappraisal [23]. As the ﬁeld of redox biology has
developed, it has become apparent that the major predictions of
the oxidative stress paradigm do not effectively explain the
biological actions of reactive species and are not supported by
experimental evidence. In this review, we propose that the
oxidative stress hypothesis has reached the limits of its utility
and should be replaced with the “redox biology paradigm” in
which antioxidants play the primary role of modulating the
complex networks controlling cell signaling and metabolism.
While it is possible that the modiﬁcations of proteins by reactive
species are an unimportant epiphenomenon, it is clear that this is
not the case; reactive species (including nitric oxide, hydrogen
peroxide, and reactive lipid species) are known to act as cell
signaling molecules, supporting the need for a reevaluation of the
oxidative stress paradigm [22,24–28]. With the discovery that nitric
oxide is a signaling molecule, the ﬁeld is now embracing the
paradigm that reactive species play an essential role in biology
and that antioxidants serve a regulatory, not a protective, function.
An important example in the ﬁeld has been the realization that one
class of reaction products from both enzymatic and nonenzymatic
lipid peroxidation is electrophilic and can selectively modify
families of cysteine-containing proteins, or electrophile-responsive
proteomes, so modulating cell function [22,29]. That these products
are derived from lipid radical targets of α-tocopherol, vitamin C, and
β-carotene likely explains the tight biological control of levels of
these molecules in human subjects and the marginal beneﬁcial
effects of supplementation [30]. In this context, the role of radical
scavenging antioxidants such as vitamin E is to control the domain
and levels of reactive lipid species for normal redox cell signaling.
The impact of these new concepts on the development of redox
therapeutics is now emerging and is discussed below.
Electrophile signaling as the master regulator of cellular
antioxidant regulation
Cells have developed intricate mechanisms by which they
sense and adapt to oxidants and electrophiles that are either
endogenous or environmental in origin. There are several stress-
responsive signaling pathways that are activated by endogenously
produced electrophiles or xenobiotics [22,29,31–34]. As with other
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signaling pathways, this is not a nonspeciﬁc or random process but
a controlled mechanism involving the posttranslational modiﬁca-
tion of redox-active cysteines in key signaling proteins. The
concept of redox signaling ﬁrst identiﬁed reactive oxygen and
nitrogen species as molecules capable of modifying reactive
cysteines, thus eliciting downstream signaling responses [35].
However, it has become evident that electrophiles may also react
with cysteine moieties via Michael addition, thereby expanding
the repertoire of reactive species having distinct signaling func-
tions. In the cellular milieu, electrophiles are produced by oxida-
tion and nitration of unsaturated fatty acids resulting in a
formation of a host of reactive species such as aldehydes, α-β-
unsaturated carbonyls, and nitroalkenes that react with cysteines
in a reversible or irreversible manner [22,29,32].
Keap1-Nrf2 pathway
One of the best characterized signaling pathways activated by
electrophiles is the Keap1-Nrf2-antioxidant response element (ARE)
pathway (Fig. 1), which orchestrates cellular responses to oxidant
and electrophile stress [22,31,36,37]. Under basal conditions, Keap1
tethers Nrf2, directing it to ubiquitination and degradation by
cullin-3-dependent proteasome. During electrophile stress, Keap1
can no longer support its function as a substrate adaptor in the
ubiquitin ligase complex, leading to stabilization of Nrf2. The key
signaling protein transducing the effects of electrophiles is Keap1,
and it has an exceptionally high number of thiol residues: a total of
25 in mouse and 27 in human. These can be extensively modiﬁed
in vitro by a variety of electrophiles.
While high enough concentrations of reactive electrophiles are able
to adduct most of the cysteine residues in recombinant Keap1, lower
concentrations yield distinct patterns of modiﬁcation [38,39]. It has
therefore been postulated that each electrophile covalently binds to a
speciﬁc set of cysteine residues within a proteome (i.e., the “cysteine
code”) and can be classiﬁed according to this feature [40]. It has also
been proposed that Keap1 perceives endogenous stress via three
phylogenetically conserved sensors that are responsive to nitric oxide,
zinc, and alkenals and that xenobiotics exploit this feature to sense
endogenous redox homeostasis [41]. Both hypotheses postulate that
Keap1 can sense very different stress stimuli, but the outcome is the
same—stabilization of Nrf2 and induction of target genes that include
antioxidant and phase II enzymes as well as other genes promoting
cell survival. In addition, to direct interactions with Keap1 many of the
kinases and phosphatases, which also modulate this pathway, possess
redox-active cysteine residues which are also potentially targets of
electrophiles [42]. Furthermore, recent ﬁndings have revealed alter-
native pathways that can degrade Nrf2. Nrf2 can bind β-transducin
repeat-containing protein (β-TrCP) via the Neh6 domain, which can be
phosphorylated by glycogen synthase kinase 3β (GSK-3β), leading
to cullin 1 (Cul1)-dependent ubiquitination and degradation of Nrf2
[43–45]. PI3K kinase is postulated to regulate the activity of GSK-3β
and thus downregulate Nrf2, suggesting that the PI3K-pathway
inhibits the activity of GSK-3β, leading to increase in Nrf2 [43].
Heat shock response (HSR)
In addition to the Keap1-Nrf2 pathway, other stress signaling
pathways are activated by electrophiles [29]. The most notable of
these is the heat shock response pathway (HSR, Fig. 1), which is a
transcriptional response to a wide array of acute and chronic stress
conditions including heat, electrophiles, and other reactive species
produced during inﬂammation [32]. HSR is regulated by heat shock
transcription factors, primarily by heat shock factor 1 (HSF1). On
activation, HSF1 undergoes multistep processing involving post-
translational modiﬁcations, nuclear enrichment, trimerization, and
binding to heat shock elements (HSEs), resulting in the transcrip-
tion of a large family of heat shock genes [32,46]. The initial trigger
causing HSR by electrophiles is not completely understood, but the
most likely candidates mediating the effects of electrophiles are
chaperone proteins HSP70 and HSP90, which repress HSF1 activa-
tion through binding and sequestration under normal conditions
[46]. Both chaperones are known to bind electrophiles such as
Fig. 1. Stress signaling pathways activated by electrophiles. (A) Heat shock response (HSR). Upon activation, heat shock factors (HSFs), primarily HSF1, translocate to the
nucleus, trimerize and bind to heat shock elements (HSEs) and drive the expression of target genes, such as heat shock proteins. (B) Keap1-Nrf2 pathway. During electrophile
stress, Keap1 is no longer able to deliver Nrf2 to proteasomal degradation, and the stabilized Nrf2 protein translocates to the nucleus, binds to antioxidant response elements
(AREs), and regulates target genes. Keap1-independent mechanisms for Nrf2 nuclear accumulation include phosphorylation of Nrf2 by PKC, PERK, or MAP Kinases. In
addition, PI3K may regulate Nrf2 via indirect mechanism by inhibiting GSK-3β activity. Active GSK-3β phosphorylates Nrf2 Neh6 domain binding protein β-TrCP, which
results in Cul1-dependent ubiquitination and degradation of Nrf2. (C) Unfolded protein response (UPR). Accumulation of misfolded proteins in the ER activates the three
arms of the UPR, resulting in activation of three transcription factors that regulate the expression of UPR target genes. PERK kinase can also phosphorylate and activate Nrf2.
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4-hydroxynonenal (HNE) [47]. Recently, two redox-active cysteine
residues have been identiﬁed in yeast HSP70 analog Ssa1 [48].
Mutation of these rendered cells insensitive to Hsf1 activation by
thiol-active compounds but not by heat shock, indicating that Ssa1
is a bona ﬁde sensor of HSR by electrophiles in yeast. Inasmuch as
HSR is an important protective pathway in proteotoxic stress,
especially in neurodegeneration, its modulation by low molecular
weight activators is of high clinical interest. Intriguingly, many of
the novel potent HSR activators identiﬁed by high-throughput
chemical screening are electrophiles that can simultaneously acti-
vate the Keap1-Nrf2 pathway, indicating that these two stress
response pathways act in concert [49,50].
Unfolded protein response (UPR)
The third stress signaling pathway known to be activated by
electrophiles is the endoplasmic reticulum (ER) stress response (ESR,
Fig. 1) [32]. ESR is triggered by accumulation of misfolded or unfolded
proteins, and is also called the unfolded protein response [51]. UPR
modiﬁes gene expression and protein translation to restore ER
protein folding and homeostasis. Three distinct UPR signaling path-
ways have been identiﬁed, each transmitted by a transmembrane
signaling protein residing in the ER: activating transcription factor-6
(ATF6), inositol requiring protein-1 (IRE1), and PERK. In addition, an
ER-resident chaperone protein 78-kDa glucose-regulated protein
(GRP78, also called BiP) is involved in the signaling, as it forms
complexes with the three UPR signaling proteins [51]. Several
mediators of the UPR can be triggered by electrophilic lipids such
as 4-HNE, oxononenal, acrolein, and cyclopentenone prostaglandins
as well as core aldehydes, such as POVPC and PEIPC, which derive
from the oxidation of phosphatidylcholine [32,52]. The mechanism
by which these electrophilic lipids activate UPR is not known.
However, the likely target(s) are chaperones in the ER: ﬂuorescently
labeled 4-HNE and cyclopentenone prostaglandins accumulate there
[15,16,53], and HNE was shown to promote the carbonylation of
Grp78 and protein disulﬁde isomerase [52]. Hence, we speculate that
direct modiﬁcation of protein chaperones in the ER results in loss of
protein folding capacity, which is consistent with previous studies
showing that HNE inhibits the protein folding function of chaperone
proteins [54].
Redox regulation of autophagy
Although it has been demonstrated that the Keap1-Nrf2 path-
way can regulate proteasomal activity, evidence to support the
concept that it also regulates the autophagy system is now
emerging [55] (Fig. 2).
Fig. 2. Redox regulation of autophagy. The Keap1-Nrf2 pathway is not only regulated by the proteasomes but also by autophagic activity. The cysteine-rich protein Keap1
serves as a redox sensor and can bind to p62 and be degraded by autophagic activity. Undegraded Keap1 complexes with Nrf2 and mediates Nrf2 ubiquitination and
degradation by the proteasomes. In response to oxidants, cysteine modiﬁcation on Keap1 releases Nrf2 by inhibiting its ubiquitination. Keap1-free Nrf2 is stabilized and
transported to the nucleus where it activates transcription of antioxidant genes, including HO-1 and NQO1, proteasomal PA28αβ, thereby increases proteasomal degradation
of oxidatively damaged proteins as well as p62, which plays an important role in autophagy by interacting with both ubiquitinated proteins and microtubule-associated
protein light chain 3 (LC3), thereby facilitates autophagy-lysosomal degradation of proteins and dysfunctional organelles such as the mitochondria. Some of the autophagy
proteins are also susceptible to cysteine modiﬁcation, examples include ATG4 which is a cysteine protease involved in pro-LC3 cleavage, LC3I to LC3II conversion by
lipidation, and LC3II to LC3I conversion by delipidation. DJ-1 is a cysteine protease playing a role in mitochondrial quality control and DJ-1 mutant mice or human Parkinson's
disease patients accumulate abnormal mitochondria.
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Autophagy is a complex pathway for protein and organelle
turnover which comprises a lysosomal-mediated degradation
process that involves 430 proteins. It involves the formation of
double membrane intracellular vesicles, recognition of speciﬁc
proteins or organelles, encircling these proteins and organelles
into autophagosomes, followed by fusion with lysosomes and
degradation of proteins and organelles [56–58]. Autophagy has
been noted to play a role in cell survival primarily during nutrient
deprivation to conserve energy and in response to stress to clear
damaged and toxic intracellular components. Autophagic activities
thus need to be highly regulated to sense intracellular stress,
through mechanisms involving cellular redox signaling [59,60].
One reported example of such regulation is based on studies of
ATG4 (AuTophaGy). ATG4 is a cysteine protease important for
cleavage of pro-LC3 to produce LC3-I, and delipidation of autop-
hagosomal outer membrane LC3-II for recycling [61,62]. ATG4 can
be modiﬁed by hydrogen peroxide on cysteine 81 (C81), and this
modiﬁcation inhibits its delipidation activity. In addition to ATG4,
DJ-1 also has redox-sensitive cysteines, and it offers a direct link
among redox signaling, autophagy, and bioenergetic dysfunction
because it regulates mitochondrial dynamics and mitophagy
[63–65]. The LC3 conjugation enzymes ATG7 and ATG3, and
lysosomal cysteine proteases, depend on cysteines for their activ-
ities; however how they are modiﬁed by cellular redox status is
unknown [66]. Loss of function due to thiol oxidation is likely
detrimental since loss of function of ATG3 or ATG7 has been
shown to result in mitochondrial dysfunction in T cells and β cells,
respectively [67–69]. Future studies to determine whether ATG4,
DJ-1, ATG3, ATG7 or other autophagy proteins are modiﬁed at
cysteine residues in vivo in different cells and in response to
different redox signals, and whether their oxidation attenuates
autophagy and cell survival are needed.
In addition to direct regulation of autophagy proteins, hydro-
gen peroxide exposure has been shown to induce cytoplasmic
ataxia-telangiectasia mutate (ATM) phosphorylation, which in
turn activates the LKB1-AMPK pathway and inactivates mTOR,
leading to autophagy activation [70]. The targets of hydrogen
peroxide in this scenario have not been identiﬁed. Redox mod-
iﬁcation of the Nrf2-Keap1 pathway has been shown to play an
important role in transcriptional regulation through the antiox-
idant response element of p62/SQSTM1—an important ubiquitin
and LC3-binding protein involved in autophagy [71] (Fig. 2).
Autophagic regulation of redox signaling
The Keap1-Nrf2-p62 interaction in autophagy regulation and redox
signaling is complex. In addition to being regulated by Nrf2 at the level
of transcription, p62 also binds Keap1 and sends Keap1 to be degraded
by autophagy, further promoting Nrf2 transcriptional activity [71–73]
(Fig. 2). In further support of a complex interaction between these
systems, liver injury was severe in the Atg7::Keap1::Alb double
knockout, but partially attenuated in the Atg7::Keap1::p62 triple
knockout mice, and prevented in the Atg7::Keap1::Nrf2 triple mutant
mice. Taken together, these data suggest that Nrf2 promotes liver
injury in the absence of autophagy, and p62 contributes to damage by
promoting Nrf2 accumulation. Furthermore, Atg7 or p62 liver knock-
out mice accumulate Keap1 protein [73]. In HepG2 cells, Keap1 levels
are highly sensitive to starvation but insensitive to the proteasome
inhibitor MG132, suggesting that autophagy plays an important role in
constitutive Keap1 degradation [73].
In addition to regulation of Nrf2-mediated redox signaling,
autophagy can also regulate cellular redox status by removing
damaged mitochondria. Dysfunctional mitochondria may generate
more reactive species due to mtDNA mutations, loss of membrane
potential, or damaged respiratory chain proteins or enzymes in the
matrix [57,60,74].
Bioenergetics and metabolism: Integration with redox
signaling
The generation and metabolism of oxidants and electrophiles
are tightly linked with the bioenergetic status of the cell. There
appears to be three levels of regulation that coordinate intracel-
lular oxidant/antioxidant status with bioenergetics. These can be
grouped into the following redox networks in the cell.
Pyridine nucleotides and energy-redox balance
Pyridine nucleotides and the balance between their oxidized
and reduced forms play critical roles in the cell. For example,
NADH is well known to carry electrons to the electron transport
chain for the generation of ATP [75]. Changes in the reduced and
oxidized states of these pyridine nucleotides are sensed by several
oxidant and antioxidant enzymes (Fig. 3).
Through the actions of nicotinamide nucleotide transhydrogenase
(NNT), NADH levels inﬂuence the phosphorylated pyridine nucleo-
tide (NADPþ/NADPH) pool [76], which is important in regulating
glutathione and used as cofactors in free radical generating enzymes
[such as NADPH oxidase (NOX) and nitric oxide synthase (NOS)].
In addition to NNT, mitochondria also regulate NADPH levels through
the actions of the NADPþ-dependent enzymes isocitrate dehydro-
genase and malic enzyme [77]. Together, these mitochondrial
enzymes act as tethers between energy metabolism and the redox
state of the cell: NNT couples its transhydrogenase activity to the
proton motive force and the latter enzymes link their NADPH-
producing capacity with their ability to oxidize metabolic substrates.
While NNT is primarily a mitochondrial enzyme, cytosolic enzymes
important in intermediary metabolism also regulate NADPH. The
most important of these is glucose-6-phosphate dehydrogenase
(G6PDH), which is the ﬁrst step in the pentose phosphate pathway
and has the capacity to generate relatively large amounts of NADPH
[78,79]. Aldose reductase (AR) is another glucose-utilizing enzyme
that has opposite effects on the NADPH pool: it can reduce sugars as
well as lipid-derived aldehydes to their respective alcohols in an
NADPH-dependent manner [80,81]. Collectively, these pathways of
intermediary metabolism necessarily modulate the antioxidant capa-
city of the cell by regulating NADPH levels.
In addition, dehydrogenase enzymes that convert reactive lipid
aldehydes to nonreactive carboxylates commonly utilize NADþ as
a cofactor. Because the NADþ/NADH ratio is a function of the
energetic state of the mitochondrion, the detoxiﬁcation capacity of
such enzymes is then envisaged to be fundamentally linked with
the energy status of the cell. This is perhaps best illustrated by the
aldehyde dehydrogenase (ALDH) class of enzymes, with particular
emphasis on mitochondria-localized ALDH2. In isolated rat liver
mitochondria, it was shown that the ability of this enzyme to
oxidize acetaldehyde was stimulated when ADP was provided.
This then suggests that aldehydes themselves may be substrates
for mitochondrial respiration and that they could contribute to
ATP generation. Indeed, the ADP/O ratio of acetaldehyde-fueled
respiration was found to be 2.6, which is similar to that with
glutamate added as substrate [82]. The linkage between the
detoxiﬁcation and respiratory activities of the enzyme is further
evinced by the fact that inhibition of mitochondrial activity with
rotenone and antimycin A abolishes acetaldehyde oxidation and
that addition of other respiratory substrates such as succinate
(which would favor a more reduced pyridine nucleotide pool)
decreases aldehyde detoxiﬁcation activity [82,83]. Hence, alde-
hyde oxidation in mitochondria is dependent upon NADþ levels
and the energy state of the organelle [84], which predicts that
pathological conditions that perturb energy and NADþ metabo-
lism will impact the detoxiﬁcation of reactive species. This appears
to be the case, especially in the context of tissue ischemia. In the
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heart, ischemia was found to decrease the NADþ/NADH ratio from
11 (under aerobic conditions) to 0.4 (during ischemia), which
contributed to a diminished ability to detoxify HNE to its corre-
sponding acid and resulted in accumulation of mitochondrial
protein-HNE adducts [85].
Oxidative posttranslational modiﬁcations of metabolic proteins
The second level of regulation involves the direct modiﬁcation
of proteins involved in intermediary metabolism (Fig. 4).
Modiﬁcations such as S-glutathiolation have been shown to have
the capacity of modulating glycolytic ﬂux as well as mitochondrial
metabolism [86], and several key glucose-handling and mitochon-
drial proteins can be modiﬁed by reactive oxygen, nitrogen, and
lipid species. Key enzymes in glucose metabolism pathways mod-
iﬁed by reactive species include glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), AR, and G6PDH. All of these enzymes have
been shown to have reactive cysteines in the active site or vicinal
thiols that can modulate catalytic activity. For example, Cys152 of
GAPDH can be modiﬁed by oxidants such as hydrogen peroxide
[87–90], nitric oxide [91,92], and nitroalkene derivatives [93].
Interestingly, the activity of AR, which converts glucose to sorbitol
and also has the capacity to reduce reactive aldehydes to their
corresponding alcohols, is tightly controlled by oxidants: oxidation
of Cys298 to a sulfenic acid results in robust activation of the
enzyme [94,95], while protein glutathiolation at the same site
inhibits its catalytic function [96]. Thus, this represents a redox
switch that can be turned on and off by different oxidative
posttranslational modiﬁcations, the addition and removal of which
are controlled by enzymes such as GSTs and glutaredoxins [97].
Interestingly, the NADPH-producing enzyme, G6PDH, is also regu-
lated by oxidation [98–102], suggesting an integrated mode of
feedback to the redox state of the cell. Hence, it appears that many
important nodes of glucose metabolism are regulated by redox-
active cysteines or nucleophiles, which are subject to modiﬁcation
by a number of reactive species. This would appear to be important
Fig. 3. Coordination of intracellular redox status with intermediary metabolic pathways. Pyridine nucleotide balance is inﬂuenced by glucose-metabolizing enzymes such as
glucose-6-phosphate dehydrogenase (G6PDH) and aldose reductase (AR). AR also utilizes NADPH in the reduction of aldehydes to their corresponding alcohols. Other
cytosolic proteins that regulate NADPH levels include NADPH oxidases (Nox) and nitric oxide synthases (NOS). In the mitochondrion, the tricarboxylic acid cycle (TCA) as well
as metabolism of aldehydes by aldehyde dehydrogenase 2 (ALDH2) can contribute to the production of NADH, which is not only used for energy transfer but can be
converted to NADPH through the actions of nicotinamide nucleotide transhydrogenase (NNT). The cytosolic enzymes malic enzyme (ME) and NADPþ-dependent isocitrate
dehydrogenase (NADPþ-IDH) utilize metabolic intermediates created in the TCA cycle to produce NADPH.
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in cellular decisions directing the ﬂux of glucose, which is not only
critical for the generation of ATP but for the synthesis of nucleotides
and phospholipids as well [103].
Mitochondria are subject to even more complex regulation by
oxidants and electrophiles. The activity of several electron trans-
port chain complexes is modulated by posttranslational modiﬁca-
tions such as S-nitros(yl)ation, S-glutathio(ny)lation, and/or
electrophile additions. In particular, complex I, the entry point of
electrons derived from NADH-producing reactions, is modiﬁed by
nitric oxide (or its derivatives) [104–108] and glutathione [109–
113]. Inhibition of complex I through S-nitrosation was shown to
be protective in the context of myocardial ischemia-reperfusion
injury [114–116], and this modiﬁcation appears to increase super-
oxide production from the complex [106,117]. Nitrotyrosine mod-
iﬁcation has also been demonstrated on the complex [118,119], as
has glutathione modiﬁcation, which appears to be evolved in this
context via thiyl radical formation [113]. Similarly, other electron
transport complexes (e.g., complexes II and V) as well as proteins
in the mitochondrial matrix (e.g., α-ketoglutarate dehydrogenase,
isocitrate dehydrogenase) have been shown to be modiﬁed by
reactive species [120–132], with the modiﬁcations, in most cases,
affecting protein catalytic activity. Interestingly, recent studies
suggest that S-nitrosation has remarkable effects on the activity
of speciﬁc pathways of mitochondrial metabolism. For example,
the enzyme very long chain acyl-coenzyme A dehydrogenase was
shown to be S-nitrosated in an endothelial NOS-dependent man-
ner, which increases the catalytic activity of the enzyme [133] and
would be thought to increase the oxidation of long chain fats in
the mitochondrion. The idea that speciﬁc modiﬁcations participate
in metabolic fuel selection in tissues is thus an exciting prospect
for future studies.
Oxidative modiﬁcations have also been shown to be critical in
the regulation of proteins involved in mitochondrial metabolic
control and cell death pathways. The adenine nucleotide trans-
porter (ANT), for example, has been shown to be modiﬁed at sites
critical for its function. Cys57, which is located on the matrix face
of the cyclophilin D binding site, has been shown to be glutathio-
lated in vivo in the hearts of inducible NOS transgenic mice [134]
and alkylated by nitro-oleate [135]. Further studies are required to
develop a more complete model of the role of such modiﬁcations
in controlling respiratory activity and protecting the mitochon-
drion from irreversible damage during conditions of high oxidant
generation.
Redox signaling and bioenergetic responses to reactive species
The integration of metabolic responses with adaptation to
rapidly changing redox environments is extremely important in
acute pathological states such as ischemia-reperfusion injury
(Fig. 5). Conditions of ischemia result in a buildup of NADH that,
upon reperfusion, creates a burst of free radicals from electron
transport chain complexes. This can further propagate lipid radical
reactions that produce electrophile species. Attempts to model this
condition in multiple cell types have yielded surprising results.
Neonatal and adult cardiomyocytes treated with HNE show
remarkable increases in both glycolytic and mitochondrial activity
[136,137], which appears to be driven both by increases in ATP
demand and proton leak. Other cell types such as smooth muscle
cells show an opposite effect, where oxygen consumption is
decreased by exposure to HNE [137]. NO and derivative species
elicit even more complex bioenergetic responses. Exposure of
cells to NO species could have multiple effects, including direct
inhibition of cytochrome oxidase; nitrosation, oxidation, or glu-
tathiolation of thiol residues; and nitration of tyrosines. Hence,
species such as peroxynitrite and S-nitrosothiols are predicted
to have differential effects on mitochondrial respiration and
glycolysis [25,138,139]. In most cases, cells with higher glycolytic
or mitochondrial reserve capacities appear more resistant to
reactive species-induced mitochondrial dysfunction [137,140]. It
is hypothesized that a higher reserve capacity could bestow the
cell with a better capacity to maintain critical ATP-dependent
processes during stress, such as ATP-dependent proteolysis
[141,142].
Redox stress can elicit signaling from mitochondria to adapt to
environmental conditions or pathological stressors. Most com-
monly, ROS such as superoxide and H2O2 are suggested to be
important for regulating the redox status of the cell and to help
maintain viability or trigger cell death [143]. The concept of ROS-
mediated signaling requires careful consideration for spatial
regulation of redox-sensitive signaling pathways, gradients
between subcellular compartments, and cause-and-effect relation-
ships. Signiﬁcant levels of superoxide production have been
shown to occur from pyruvate dehydrogenase, oxoglutarate dehy-
drogenase, complex I, electron transfer ﬂavoprotein ubiquinone
oxidoreductase, and glycerol-3-phosphate dehydrogenase [144].
The generation of superoxide, in most cases, leads to the produc-
tion of H2O2, which is more stable and able to diffuse across
biological membranes. These characteristics impart the molecule
with an ability to propagate signal transduction. For example,
growth factor-mediated signaling requires H2O2 [145,146], and
Fig. 4. Oxidative modiﬁcation of metabolic proteins. The cysteine side chains of
multiple metabolic proteins are modiﬁed by reactive species. Modiﬁcations such as
sulfenic acid (-SOH), sulﬁnic and sulfonic acids (-SO2/3H), electrophile adducts
(e.g., by reactive lipids; -S-lipid), glutathiolation (-SSG), and S-nitrosation (-SNO)
can regulate protein activity and promote adaptive responses in metabolism that
can regulate cytoprotection or promote cell death.
Fig. 5. Redox signaling and bioenergetic responses to reactive species. The
response of the mitochondrion to reactive species can inﬂuence cell signaling
pathways or activate pathways of protein degradation, such as autophagy. Reactive
species such as HNE can regulate ATP production and turnover. In addition,
conditions such as ischemia result in mitochondrial H2O2 generation which
participates in redox signaling, leading to adaptive responses to stress.
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H2O2 has been shown to be critical in protein phosphorylation-
mediated signaling, as it oxidizes critical cysteine residues of
protein phosphatases [147]. Retrograde, superoxide/hydrogen
peroxide-dependent signaling from mitochondria has also been
shown to be important to quality control processes in the cell,
such as autophagy [59]. Not surprisingly, this third level regulation
is highly linked with pyridine nucleotides and oxidative modiﬁca-
tions. Bioenergetic responses to stress may be initiated by changes
in pyridine nucleotides and substrate availability, and oxidative
modiﬁcations such as protein glutathiolation of respiratory com-
plexes regulate mitochondria-derived superoxide or hydrogen
peroxide, which could direct cell signaling.
Therapeutic applications
The notion that multiple antioxidant and cytoprotective genes
could be induced by a single molecule via activation of stress signaling
pathways has attracted considerable attention in drug development,
as this approach is potentially attractive for many disease processes in
which oxidative stress and inﬂammation play a role [148,149]. The
ﬁrst molecules that were tested were derived from plants. The most
commonly used of these is sulforaphane, which is usually adminis-
tered in the form of broccoli extract. Sulforaphane was ﬁrst used for
chemoprevention and its primary mode of action is the activation of
the Keap1-Nrf2 pathway, although it has other signaling effects such
as the inhibition of NF-κB [150]. Other indications have followed, and
the NIH clinical trial registry ClinicalTrials.gov now lists a total of 26
trials for conditions ranging from chronic obstructive pulmonary
disease (COPD) to sickle cell disease.
Apart from sulforaphane, several other Nrf2 activating drugs
have entered clinical development. Bardoxolone methyl, a triter-
penoid and potent Nrf2 activator, was acquired from Reata by
Abbott for clinical development [151]. However, while a Phase II
study (BEAM) for chronic kidney disease in type II diabetics
showed an improvement in kidney function assessed by glomer-
ular ﬁltration rate, the Phase III study was terminated due to a
higher rate of cardiovascular events than with placebo, which
prompted termination of the trial [152]. Subsequently, all other
clinical trials with the compound were halted. However, dimethyl
fumarate, another Nrf2 activator that was initially developed as an
oral treatment for psoriasis in 1950s, was proven to be effective in
multiple sclerosis (MS) in two Phase III clinical trials where the
number of relapses and lesions detected by MRI and the rate of
disability progression were decreased, without any serious adverse
effects [153,154]. The drug is now approved by FDA and European
Medicines Agency (EMA) for relapsing forms of MS. Of note, in
preclinical animal studies, dimethyl fumarate has been shown to
protect against cardiac ischemia-perfusion injury via activation of
Nrf2, suggesting that other indications may soon follow [155].
In addition fatty acid-derived electrophilic compounds such as
cyclopentenone prostaglandins and nitroalkenes have been tested in
preclinical studies and likely possess convergent mechanisms of action
[156]. For example, 15d-PGJ2 has been shown to attenuate inﬂamma-
tion via the Keap1-Nrf2 pathway and other redox-sensitive pathways
in a number of models of inﬂammation [157–159]. Electrophilic
neurite outgrowth-promoting prostaglandin (NEPP) compounds have
been developed based on the chemical structures of cyclopentenone
prostaglandins [160], and one of these, NEPP11, was found to be
protective against ischemia-reperfusion injury in mice via Nrf2 activa-
tion [161]. There is a wealth of preclinical evidence of the protective
effects of nitroalkenes, OA-NO2 in particular, in various animal models
of metabolic and inﬂammatory disorders [29]. These are now in
clinical development for the treatment of diseases associated with
kidney injury, inﬂammation, and metabolic disorders, the initial
clinical target being contrast imaging, dye-induced nephropathy.
While the success of dimethyl fumarate has increased enthusiasm
for the use of Nrf2 activating drugs for various degenerative diseases,
there are issues that warrant attention. The mode of action of the
majority of Nrf2 activating agents developed to date is via covalent
adduction of Keap1 thiol residues, and practically all have other targets
as well. An important aspect of electrophilic signaling is that the
covalent modiﬁcation of a signaling molecule can accumulate slowly
over time with a progressive activation of a signaling pathway [162].
This has important implications in the pharmacological application of
electrophiles because the cellular response to electrophiles is typically
biphasic, with activation of protective signaling pathways occurring at
low concentrations and promotion of ER stress and cell death as
exposure increases [34,39,140,163]. The mitochondria of highly ener-
getic tissues such as the heart and kidney are particularly vulnerable
with extended exposures to electrophiles and thus are susceptible to
electrophile-dependent toxicity. This phenomenon may well explain
the cardiotoxic effects of bardoxolone methyl [152]. Furthermore, the
detoxiﬁcation pathways for electrophiles vary in human populations,
suggesting, as with other therapies, the need for a personalized
medicine approach [164–166]. Classical pharmacological approaches
for determining the bioavailability and pharmacokinetics of electro-
philes are hampered by their reactivity with nucleophilic residues,
particularly cysteine. Since with some electrophiles these covalent
adducts are reversible in the presence of other nucleophiles there is
potential for a reservoir of electrophilic therapeutics to accumulate
during long-term dosing. As noted above, the cell signaling effects of
electrophiles also accumulate over time and this can greatly enhance
their potency [162]. Clearly, a new approach to the pharmacology of
electrophiles will be needed to understand how these molecules
interact with both normal and diseased cells. At a minimum monitor-
ing the extent of thiol modiﬁcation over time may be necessary to
achieve an effective therapeutic index.
Underlying the potential toxicity of electrophiles is the fact that
the “cysteine code” and the resulting electrophile-responsive
proteome are distinct for each electrophile [33,167]. This is
potentially important in dictating off-target effects, as exempliﬁed
by differences in side effects between bardoxolone methyl and
dimethyl fumarate. Another important factor to take into con-
sideration is the possibility of adverse effects of Nrf2 activation.
Although Nrf2 is used for chemoprevention, constitutively over-
active Nrf2 is common in certain cancers, promoting cancer cell
proliferation and chemoresistance [31]. Conceptually, an interest-
ing idea is emerging in which the consequence of hyperactivation
of the Nrf2 system is a “reductive stress” with attendant unique
redox-related pathologies [168]. While it has been argued that
high levels of Nrf2 activity present in cancer cells where the
Keap1-Nrf2 system is dysregulated are not attainable by Nrf2
activating drugs, only long-term use of these drugs will reveal
whether their use is associated with a higher incidence of cancer.
In addition to cancer cell growth promoting effects, Nrf2 has
metabolic effects that are still somewhat ill-characterized and
controversial. Paradoxically, the loss of Nrf2 in hypercholestero-
lemic, ApoE-deﬁcient mice protects against atherosclerosis
[169–171], yet its absence in bone marrow-derived cells is proathero-
genic [172,173], suggesting a link between Nrf2 and atherosclerosis
that is cell-type speciﬁc. In addition, Nrf2 affects liver and adipose
tissue lipid and glucose metabolism and thus Nrf2 activation may
have unfavorable systemic metabolic effects [174].
Summary
Our understanding of the redox biology of the cell has matured
since the ﬁrst simple concepts underlying the oxidative stress para-
digm. The translational application of the key idea that supplementa-
tion with oxidant scavenging will prevent or reverse pathologies
A.-L. Levonen et al. / Free Radical Biology and Medicine 71 (2014) 196–207 203
associated with oxidative stress has not been successful. However, in
the course of these studies a new perspective has emerged. The
central idea is that redox-active mediators such as nitric oxide,
hydrogen peroxide, and lipid electrophiles act as site-speciﬁc media-
tors of cell signaling: protein cysteine residues are the sensors or
receptors of these different redox mediators and the “traditional”
antioxidants such as glutathione and α-tocopherol serve the essential
function of insulating distinct redox signaling domains in the cell from
cross-talk. Interestingly, an important implication of these ideas is that
targeting of redox therapeutics will dramatically alter their pharma-
cological effects. Pathology is associated with dysregulation of these
pathways and this can affect metabolism, autophagy, cell growth, and
repair. The most successful translational exploitation of these path-
ways to date has been the selective activation of the Keap1-Nrf2
system. As with all new therapeutics the application of selective
modulators of this pathway is revealing how much we have yet to
learn about this growing ﬁeld of redox biology.
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